BMRN BioMarin Pharmaceutical Inc.

-0.94  -1%
Previous Close 88.81
Open 86.14
Price To Book 5.37
Market Cap 15646317254
Shares 178,062,106
Volume 2,361,773
Short Ratio
Av. Daily Volume 945,379

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment to be completed 2Q 2019.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A
Phase 3 top-line data due end of 2019.
Approval announced May 24, 2018.
Palynziq (Pegvaliase)
Phenylketonuria (PKU)
Program terminated June 2016
Reveglucosidase alfa (BMN 701)
Pompe Disease
Approved February 14, 2014.
Vimizim (GALNS)
(MPS IVA) Morquio A Syndrome
PDUFA date extended by three months to April 27 2017. Approval announced April 27, 2017.
Cerliponase alfa
Batten Disease
CRL issued January 14, 2016.
Duchenne Muscular Dystrophy (DMD)
Phase 1/2 update May 22, 2018 noted 97% decrease in bleeding rate. Further data due May 2019 with BLA filing due 2H 2019.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A
Phase 1/2 dosing has commenced - noted May 15, 2018.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A with with pre-existing AAV5 antibodies
Phase 2 commencement of dosing announced June 14, 2018.
Achondroplasia - young children

Latest News

  1. Can This Biotech Stock Redeem Its Sales Lag With A Strong Gene Therapy?
  2. BioMarin Pharmaceutical Inc. (BMRN) Q4 2018 Earnings Conference Call Transcript
  3. BioMarin (BMRN) Q4 Earnings & Sales Miss, Shares Decline
  4. The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data
  5. BioMarin: 4Q Earnings Snapshot
  6. BioMarin Announces Full Year and Fourth Quarter 2018 Results
  7. FOMC minutes, Walmart earnings – What to know in the week ahead
  8. The typical Facebook employee earns double Silicon Valley's median household income. How 50+ big tech employers compare
  9. BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
  10. Market Trends Toward New Normal in Brighthouse Financial, BioMarin Pharmaceutical, EZCORP, Assembly Biosciences, A-Mark Precious Metals, and American Public Education — Emerging Consolidated Expectations, Analyst Ratings
  11. Is Sangamo's Gene-Editing Approach a Bust?
  12. The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs
  13. See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
  14. BioMarin Announces Ongoing Study Demonstrates Durable Treatment Benefit from Brineura® (cerliponase alfa) for 3 Years
  15. BioMarin Announces 14 Presentations at 15th Annual WORLDSymposium™ 2019
  16. 3 Gene Therapy Stocks With Huge Catalysts in 2019
  17. Biotech Conference Highlights Pipeline at BioMarin
  18. Is BioMarin Pharmaceutical Inc.’s (NASDAQ:BMRN) Balance Sheet Strong Enough To Weather A Storm?
  19. BioMarin to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast on Thursday, February 21 at 4:30pm ET